Drug search by name

Adalat CC and Renal dysfunction

Result of checking the interaction of drug Adalat CC and disease Renal dysfunction for safety when used together.

Check result:

Adalat CC <> Renal dysfunction

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Although the clearance of nifedipine is not dependent on renal function, use of the drug in patients with uremia has been associated with enhanced pharmacologic effects, possibly due to increased sensitivity to the drug or reduced protein binding. Rarely, reversible elevations in BUN and serum creatinine have been reported in patients with preexisting chronic renal insufficiency given nifedipine, although a causal relationship has not been established. Nephritis and renal failure have also been observed. Therapy with nifedipine should be administered cautiously in patients with significantly impaired renal function.

References:

Zucchelli P, Zuccala A, Borghi M, et al "Long-term comparison between captopril and nifedipine in the progression of renal insufficiency." Kidney Int 42 (1992): 452-8
Cacoub P, Deray JY, Deray G, et al "Nifedipine-induced acute renal failure." Clin Nephrol 29 (1988): 272-3
van Bortel L, Bohm R, Mooij J, et al "Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure." Eur J Clin Pharmacol 37 (1989): 185-9
Kleinbloesem CH, van Brummelen P, van Harten J, et al "Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship." Clin Pharmacol Ther 37 (1985): 563-74
Diamond JR, Cheung JY, Fang LS "Nifedipine-induced renal dysfunction." Am J Med 77 (1984): 905-9
Diamond JR, Cheung JY, Fang LST "Nifedipine-induced renal dysfunction." Am J Med 77 (1984): 905-9
"Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.
Robertson DR, Waller DG, Renwick AG, George CF "Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine." Br J Clin Pharmacol 25 (1988): 297-305
Ene MD, Roberts CJ "Pharmacokinetics of nifedipine after oral administration in chronic liver disease." J Clin Pharmacol 27 (1987): 1001-4
Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983): 113-24
Scoble JE, Uff JS, Eastwood B "Nifedipine nephritis." Clin Nephrol 21 (1984): 302
Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986): 425-49
Eicher JC, Morelon P, Chalopin JM, et al "Acute renal failure during nifedipine therapy in a patient with congestive heart failure." Crit Care Med 16 (1988): 1163-4
McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985): b30-40
Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996): 921-8
"Product Information. Adalat (nifedipine)." Bayer, West Haven, CT.
Hall-Craggs M, Light PD, Peters RW "Development of immune complex nephritis during treatment with the calcium channel-blocking agent nifedipine." Hum Pathol 15 (1984): 691-4